Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biopharmaceutical company, has promoted Thomas Englese to the position of chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will continue to oversee sales, marketing, market access, and commercial operations for the company’s key products, including TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg) for the management of fibromyalgia in adults, as well as Zembrace® SymTouch® and Tosymra® for the acute treatment of migraine in adults.
This promotion comes at a critical juncture for Tonix as it seeks to solidify its position in the CNS therapeutic area. Seth Lederman, President and CEO of Tonix, emphasized Englese’s instrumental role in building the company’s commercial organization and leading the launch of TONMYA, which is the first new treatment for fibromyalgia in over 15 years. Englese’s expanded title reflects the company’s confidence in his leadership as it aims to broaden the product’s reach and drive sales growth.
In a statement, Englese expressed his commitment to expanding patient access, growing the prescriber base, and increasing sales as Tonix continues to scale up the TONMYA launch. His strategic oversight is expected to be pivotal in navigating the competitive landscape of fibromyalgia treatments and capitalizing on the product’s unique position as a novel therapeutic option.
The significance of this executive change extends beyond internal corporate restructuring. It underscores Tonix’s strategic focus on maximizing the commercial potential of its flagship product, TONMYA. The drug’s approval marked a milestone in a therapeutic area that has seen limited innovation, and the company is now investing in a robust commercial infrastructure to ensure its success. Englese’s promotion signals a dedicated effort to strengthen market penetration and build lasting relationships with healthcare providers and patients.
Tonix’s commitment to CNS disorders is further evidenced by its ongoing clinical development programs. The company is evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, exploring its potential beyond fibromyalgia. Additionally, Tonix’s CNS pipeline includes TNX-2900 for Prader-Willi syndrome, a rare disease, which is Phase 2 ready. Beyond CNS, the company is advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
The promotion of Englese is likely to be viewed positively by investors, as it demonstrates a clear strategic direction and a focus on commercial execution. The company’s ability to successfully launch and scale TONMYA will be a key driver of its near-term financial performance and long-term growth. With Englese at the helm of commercial operations, Tonix is positioning itself to capitalize on the significant market opportunity presented by fibromyalgia, a condition that affects millions of people worldwide and has historically had limited treatment options.
For more information, visit https://ibn.fm/uzRyl and the company’s newsroom at https://ibn.fm/TNXP.
